A blinded, randomized, placebo‐controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel(®)) in client‐owned dogs with atopic dermatitis

BACKGROUND: Pruritus is the hallmark clinical sign of atopic dermatitis (AD) in dogs. Preliminary study results suggest that oclacitinib, a selective Janus kinase inhibitor, could reduce pruritus and associated inflammatory skin lesions in dogs with AD. HYPOTHESIS/OBJECTIVES: The objective was to ev...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Vet Dermatol
Autors principals: Cosgrove, Sallie B., Wren, Jody A., Cleaver, Dawn M., Walsh, Kelly F., Follis, Stacey I., King, Vickie I., Tena, Jezaniah‐Kira S., Stegemann, Michael R.
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Science 2013
Matèries:
Scientific Papers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4286885/
https://ncbi.nlm.nih.gov/pubmed/24581322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/vde.12088
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars